FDA made a public relations mistake in its handling of the controversial approval of Zogenix Inc.'s hydrocodone Zohydro ER, Commissioner Robert Califf acknowledged during a March 2 Senate Appropriations subcommittee hearing.
The agency should have conducted another advisory committee meeting to consider the proposed post-marketing plan for the opioid product without abuse-deterrent features to show that FDA had addressed the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?